In this episode we're exploring some controversial issues in cancer research including real world versus clinical trial experience and immune related toxicities, as well as highlighting strength and weaknesses around some encouraging new data with several therapies in development for different hematologic malignancies.
Not everything about cancer immunotherapies is positive -- there are challenges associated with this promising approach too. Despite what many people may believe, it's not just about merely tweaking one's immune system and the cancer goes away.
Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Society of Hematology (ASH) in Atlanta.
In this episode you'll hear leading experts, including Drs Paul Richardson and Philippe Armande (Dana-Farber), Dr John Leonard (Weill Cornell), Dr Ian Flinn (Sarah Cannon), Dr Nancy Simonian (Syros) and Drs Michael Wenger and Deepak Sampath (Genentech).
Some of the topics covered include: